To investigate if the CD44 antibody KM114 required Myd88 expression for the amelioration of murine ITP, we also treated Myd88 deficient and control mice with KM114 in the ITP model and found that both control mice (Figure 5, column 4) and Myd88 deficient mice (Figure 5, column 8) were protected from thrombocytopenia, with no significant difference in platelet counts between the 2 groups. This evidence concerns the gene CD44 and autoimmune thrombocytopenic purpura.